Aptamers as Innovative Tools for Prostate Cancer: Tumor Recognition and Biological Activity
Biomolecules · 2026
DOI: 10.3390/biom16101412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Tayanne Felippe Sassaro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Genômica Aplicada e Bioinovações, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, Brazil. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Prostatic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Oswaldo Cruz Foundation, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Prostate cancer (PC) is the second most common malignancy among men worldwide and remains a leading cause of cancer-related mortality, highlighting the need for novel molecular tools for diagnosis and targeted therapy. In this study, five DNA aptamers (AptaP1–AptaP5) generated by Cell-SELEX against the LNCaP prostate cancer cell line were characterized for their structural features, tumor recognition, and biological activity. Secondary structure prediction and thermodynamic stability were evaluated in silico. Aptamer recognition was evaluated by flow cytometry in prostate cancer cell lines and by complementary aptafluorescence analyses in both cell lines and a prostate tissue microarray (TMA), while functional effects were evaluated by assessment of metabolic activity and proliferation assays. The selected aptamers preferentially recognized LNCaP and DU145 cells over RWPE-1, whereas no tumor-selective binding was observed for PC3 cells. Aptafluorescence analyses in the prostate TMA demonstrated differential tissue recognition, with signals detected across both primary and metastatic prostate cancer specimens. Moreover, all aptamers significantly reduced metabolic activity and proliferation in prostate cancer cells after 48 h of treatment. Collectively, these findings characterized novel DNA aptamers with promising potential as tools for prostate cancer detection and provide a basis for further investigation of their binding properties and biological effects in clinically relevant models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Genômica Aplicada e Bioinovações, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, Brazil.
- Divisão de Patologia (DIPAT), Instituto Nacional do Câncer (INCA), Rio de Janeiro 20220-400, Brazil.
ORCID-Profile: Aline Dos Santos Moreira, Rayane da Silva Abreu, Wim Maurits Sylvain Degrave, Mariana Caldas Waghabi
Förderung
- National Council for Scientific and Technological Development
- Oswaldo Cruz Foundation
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
Zitieren
APA
Sassaro, T. F., Ferreira, D. D. P., Moreira, A. D. S., Abreu, R. D. S., de Araújo, N. S., Bastos, N. C., Fernandes, P. V., Degrave, W. M. S., & Waghabi, M. C. (2026). Aptamers as Innovative Tools for Prostate Cancer: Tumor Recognition and Biological Activity. Biomolecules. https://doi.org/10.3390/biom16101412
Vancouver
Sassaro TF, Ferreira DDP, Moreira ADS, Abreu RDS, de Araújo NS, Bastos NC, et al. Aptamers as Innovative Tools for Prostate Cancer: Tumor Recognition and Biological Activity. Biomolecules. 2026. doi:10.3390/biom16101412
BibTeX
@article{Sassaro2026,
author = {Sassaro, Tayanne Felippe and Ferreira, Danielle Dias Pinto and Moreira, Aline Dos Santos and Abreu, Rayane da Silva and de Araújo, Natassia Silva and Bastos, Nina Carrossini and Fernandes, Priscila Valverde and Degrave, Wim Maurits Sylvain and Waghabi, Mariana Caldas},
title = {Aptamers as Innovative Tools for Prostate Cancer: Tumor Recognition and Biological Activity},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16101412}
}
EUVIMED